Kub5-Hera(RPRD1B) deficiency promotes “BRCAness” and vulnerability to PARP inhibition in BRCA-proficient Breast Cancers

PURPOSE: Identification of novel strategies to expand the use of PARP inhibitors beyond BRCA deficiency is of great interest in personalized medicine. Here, we investigated the unannotated role of Kub5-Hera(RPRD1B) in homologous recombination (HR) repair and its potential clinical significance in ta...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: Motea, Edward A., Fattah, Farjana J., Xiao, Ling, Girard, Luc, Rommel, Amy, Morales, Julio C., Patidar, Praveen L., Zhou, Yunyun, Porter, Andrew C., Xie, Yang, Minna, John D., Boothman, David A.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6295248/
https://ncbi.nlm.nih.gov/pubmed/30108102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1118
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires